KPV peptide: what it is, what the studies tested, and where FDA review stands

What is KPV?

KPV is a peptide, a short chain of amino acids, made of lysine (K), proline (P), and valine (V). FDA's July 2026 briefing says the body makes it naturally. It is a fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), which the pituitary gland makes.

A 2008 mouse study places KPV at positions 11 to 13 of alpha-MSH. Alpha-MSH acts through melanocortin receptors, proteins on cells that receive its signal. FDA's review cites lab evidence that these receptors are unlikely to be KPV's targets. It concludes that KPV's molecular targets remain unknown.

FDA reviewed two forms. KPV free base is the peptide by itself. KPV acetate is a salt form of the same peptide, and FDA treats the two as different active ingredients. KPV is a common name, with no United States Adopted Name, the official U.S. drug name.

FDA staff found that neither form is well characterized. Public records lacked full testing for impurities, clumps, and microbes. Staff also found different salts and related molecules sold under the same name. A patient could then receive a different substance than the physician ordered.

What is KPV peptide good for? What the studies tested

No use in people has been shown. The main KPV studies tested cells in dishes, mice with gut inflammation (colitis), obese mice, and donated skin in the lab. Other records include fat, liver, skin, and eye cells. FDA's briefing says none of the nine nomination references studied KPV given to people.

• Dalmasso and colleagues, 2008, Gastroenterology. Model: human gut-lining cells and human immune T cells in dishes, plus two chemical colitis models in mice. Route: added to the cells; given to mice in drinking water. Measured: inflammation signals in cells, and colon tissue and inflammation genes in mice. Found: lower inflammation signals and less colitis. People studied: none.
• Kannengiesser and colleagues, 2008, Inflammatory Bowel Diseases. Model: two colitis models in mice, including mice lacking a working MC1R, one of the melanocortin receptors. Route: not stated in the study summary. Measured: weight loss, colon tissue, and an inflammation enzyme. Found: faster recovery, more weight regained, and less inflammation; all treated MC1R-deficient mice survived colitis. People studied: none.
• Xiao and colleagues, 2017, Molecular Therapy. Model: mice with colitis. Route: by mouth, with KPV packed in tiny engineered particles made with hyaluronic acid, inside a gel. Measured: gut-lining damage and TNF-alpha, an inflammation signal. Found: less damage and lower TNF-alpha than a simpler particle gel. People studied: none.
• An and colleagues, 2026, Tissue and Cell. Model: fat cells in dishes and mice fed a high-fat diet. Route: added to cells; given to mice by mouth. Measured: fat-cell development, body weight gain, fat tissue, liver mass, and blood fats. Found: less body weight gain and less fat-tissue expansion in mice. People studied: none.
• Pawar and colleagues, 2017, as described in FDA's briefing. Model: skin from human donors after death, tested in the lab. Route: placed on the skin, with and without an electric current or microneedle scraping. Measured: how far KPV moved into the skin. Found: KPV passed poorly through skin, and both methods increased entry. Living people studied: none.
• Three rodent wound studies from 2003, 2006, and 2022, as summarized by FDA. Model: rodents with wounds. Route: not detailed in the briefing. Measured: wound healing. Found: FDA describes KPV as effective in these rodent models. People studied: none.

Where the KPV study record stops

The mouse results came from KPV in drinking water or inside engineered particles. Those forms differ from the creams, oral products, injections, and nasal sprays that websites promote.

ClinicalTrials.gov, the public registry of planned and running studies, listed no KPV study on September 18, 2026. A PubMed search that day returned 42 KPV records. By title and record type, they are cell, animal, skin-sample, chemistry, and review papers, and none is a clinical trial.

How strong is the evidence? The Peptide Field has not assigned KPV an evidence grade. The current record sits at the cell and animal levels.

What KPV sellers claim and what the studies measured

FDA's briefing summarizes what websites say about KPV. They promote it for inflammation, wound healing, skin health, immunity, nerve damage, stroke, and gut health. Other claims include psoriasis, colitis, Crohn's disease, histamine intolerance, Lyme disease, and recovery from COVID-19. FDA wrote that it is unclear whether compounded products are used for all of these.

The same websites offer KPV as an injection, an oral product, a topical product, and a nasal spray. Some mix it with BPC-157, TB-500, AOD-9604, and Follistatin-344. Larger compounding sites registered with FDA under section 503B reported making no KPV products from January 2017 to June 2025.

FDA reviewed a nomination for a topical cream or gel for wounds and inflammatory conditions. The lab record covers gut inflammation, obesity, and wound models in mice, plus donated skin and several cell types. FDA found no study that tested a website claim in people.

A 2026 mouse study found less weight gain in mice fed a high-fat diet and given KPV by mouth. Another mouse study found more weight regained during recovery from colitis. Neither result shows what KPV does to weight in people.

KPV has no site evidence grade. The website claims rest on cell and animal studies at most.

What is the difference between KPV and BPC-157?

KPV has 3 amino acids, and FDA found no studies of it in people. BPC-157 has 15 amino acids, and FDA's 2026 briefing lists five clinical studies that used it. Neither is part of an FDA-approved drug. FDA staff advised against adding either to the 503A Bulks List, which names substances certain pharmacies may compound with.

• Origin: KPV is the last three amino acids of alpha-MSH, a pituitary hormone. BPC-157 is a fragment of a protein first isolated from human gastric juice.
• Largest human study: KPV has none on record. For BPC-157, 53 people with ulcerative colitis received a daily enema of BPC-157 or placebo, an inactive comparison, for two weeks. That trial appeared only as a meeting abstract, and FDA judged its data inadequate.
• July 2026 committee vote: PharmExec reported an 8 to 6 vote to add KPV, BPC-157, and TB-500 to the 503A Bulks List.
• WADA 2026 Prohibited List: BPC-157 is named in class S0, which bans substances with no government approval for human therapeutic use at all times. KPV is not named, though class S0 may apply.
• Evidence grade at The Peptide Field: BPC-157 is graded Emerging, meaning some studies in people exist and major questions remain. KPV has no grade.
• Studied together: the PubMed search found no study that tested KPV and BPC-157 as a combination.

Is KPV safe? What FDA found about side effects

FDA's May 2026 briefing says it found no clinical studies or human exposure data for KPV by any route. FDA therefore could not determine its potential safety risks in people.

FDA searched its adverse event reporting system (FAERS) and the medical literature through December 3, 2025. Neither search found a report of a side effect tied to KPV. A search of FDA's food and supplement complaint system, from January 2004 through December 3, 2025, found no KPV cases.

FDA states that it cannot make firm conclusions about KPV safety from its adverse-event reports alone. Reporting is voluntary, and pharmacies that compound under section 503A generally do not report adverse events to FDA.

FDA found no toxicity studies of KPV after one dose or after repeated doses. It found none on gene damage, reproduction, or cancer, and no study of how the body absorbs and clears KPV.

FDA raised two further concerns. The immune system may react to a peptide, with results ranging from antibodies with no visible effect to life-threatening reactions. Peptides can also clump together (aggregate), which adds to that immune risk. FDA found too little data to conclude that KPV avoids either risk.

FDA's compounding safety-risk page, current as of April 22, 2026, lists KPV. It says FDA lacks information on whether KPV would cause harm in people. A licensed clinician can compare these gaps with a person's health history.

Is KPV FDA approved?

No. FDA's 2026 briefing says neither KPV free base nor KPV acetate is part of any FDA-approved drug. Neither form has a USP monograph, the official U.S. quality standard for a drug ingredient. The European Medicines Agency lists no authorized product that contains KPV.

The original KPV nomination for the 503A Bulks List was withdrawn. FDA then reviewed both forms on its own. Staff concluded that the criteria weigh against adding either form to the list.

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee discussed KPV for wound healing and inflammatory conditions. PharmExec reported an 8 to 6 vote in favor of adding KPV, with one abstention. FDA's meeting page posts no vote results, so those figures come only from PharmExec.

The committee's advice does not bind FDA, and any change would require formal rulemaking with public notice and comment. A lawyer quoted by PharmExec estimated eight to twelve months before pharmacies would have clear legal authority.

How to check a KPV claim

Four questions test any KPV claim, whether it appears on a clinic menu, a vial listing, or an ad. Answer each one for the exact product, using a record you can name. If any answer is no or unknown, the claim is not established for that product.

Use the site's claim-checking guide for a source-linked version of these questions.

• Was the claim tested in people? For KPV, FDA found no human studies, and the registry listed none.
• Does the study match the product's form and route? The mouse results used drinking water or engineered particles, and the skin work used donated skin.
• Did the study measure a health result, or only a lab marker such as an inflammation signal? The KPV records measured markers and tissue changes in cells and mice.
• Is the product FDA-approved for that use? For KPV, FDA's 2026 briefing answers no.